Skip to main content

A clinician’s perspective on the value of TBI biomarkers

15 Jun 2021
B - Breakout stage 2
Quality and Clinical Improvement

Worldwide each year, more than 50 million people sustain a traumatic brain injury (TBI). Symptoms resolve quickly for many patients, while others can take several weeks to months for post-concussive symptoms to resolve, and yet another subset of patients continues to experience persistent symptoms for three months or more after injury. However, due to the limitations of currently used evaluation tools, TBI can be challenging to adequately screen, manage and develop therapeutic treatments to improve outcomes.

Hear from a leading expert about effective strategies and trends related to head injury evaluation and an update regarding potential advances in biomarker research. Biomarkers have the potential to aid in the evaluation of TBI and have demonstrated the ability to predict the absence of intracranial injury. Two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers for clinical use to predict traumatic intracranial injuries on head CT scan acutely after TBI.

During this session delegates will:

  • gain an understanding of the unmet needs and challenges regarding the current tools and approach to traumatic brain injury evaluation
  • examine how the current approach to TBI evaluation impacts patient care and burden to the hospital
  • discuss the long-term impact of mild TBI and what emergency departments can do to improve outcomes
  • identify developments regarding the use of biomarkers for TBI evaluation and discuss the ways in which biomarkers may be used in the future clinically to improve patient care.

This session is delivered in partnership with Abbott Point of Care

Dr Paul Jarvis, Global Medical Affairs Director - Abbott Point of Care
Dr Alastair Jones, Consultant in Emergency Medicine and Sports Medicine & Musculoskeletal Physician - Bradford Royal Infirmary